Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02743637 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
A Phase 1 study, sponsored by SynDevRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT02743637 is a Phase 1 study that has completed, run by SynDevRx. The registered enrollment target is 32 participants.
The verdict
NCT02743637, a Phase 1 study, has completed, sponsored by SynDevRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
Interventions
- DRUG SDX-7320
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02743637
The ClinicalTrials.gov registry entry for NCT02743637 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SynDevRx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SDX-7320 is the first listed.
NCT02743637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02743637 about?
NCT02743637 is a clinical study titled "A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors". This is a Phase 1 dose escalation to assess the safety, tolerability and maximum tolerated dose of subcutaneous administered SDX-7320 in patients with advanced refractory or late-stage solid tumors.
What is the current status of trial NCT02743637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2016-02. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT02743637?
The interventions under investigation include: SDX-7320 (DRUG).
Who is sponsoring clinical trial NCT02743637?
This trial is sponsored by SynDevRx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.